LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors. - Wikidata - awgldk - TriplyDB

LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors.

LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors.

http://www.wikidata.org/entity/Q34425580

about

Investigation on quantitative structure activity relationships and pharmacophore modeling of a series of mGluR2 antagonists Effect of the umami peptides on the ligand binding and function of rat mGlu4a receptor might implicate this receptor in the monosodium glutamate taste transduction The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors Cocaine and kindling alter the sensitivity of group II and III metabotropic glutamate receptors in the central amygdala.Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge.A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices.Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: II. Glutamate (Ant)agonists.From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.Developmental regulation of hippocampal excitatory synaptic transmission by metabotropic glutamate receptors.Orbitofrontal cortex neurons as a common target for classic and glutamatergic antipsychotic drugs.Activation of synaptic group II metabotropic glutamate receptors induces long-term depression at GABAergic synapses in CNS neurons.Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks Metabotropic glutamate receptor ligands as potential therapeutics for addiction Metabotropic glutamate receptors as therapeutic targets for schizophrenia.Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans.Allosteric modulation of Class C GPCRs: a novel approach for the treatment of CNS disorders.Dissecting the molecular pathways of primary aldosteronism.Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators.Type 2 metabotropic glutamate receptor (mGluR2) fails to negatively couple to cGMP in stably transfected cells.Opposite effects of Zn on the in vitro binding of [3H]LY354740 to recombinant and native metabotropic glutamate 2 and 3 receptors.Systemic pre-treatment with a group II mGlu agonist, LY379268, reduces hyperalgesia in vivo.Enantioselective oxidative gold catalysis enabled by a designed chiral P,N-bidentate ligand.Presynaptic group II mGluR inhibition of short-term depression in the medial perforant path of the dentate gyrus in vitro.Changes in rat serum corticosterone after treatment with metabotropic glutamate receptor agonists or antagonists.Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors.Efficient synthesis of cyclopropane-fused heterocycles with bromoethylsulfonium salt.Group II and III metabotropic glutamate receptors suppress excitatory synaptic transmission in the dorsolateral bed nucleus of the stria terminalis.Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography.Cross-compartmental Modulation of Dendritic Signals for Retinal Direction Selectivity.Effect of the group II metabotropic glutamate agonist, 2R,4R-APDC, varies with age, layer, and visual experience in the visual cortex.Astrocyte VAMP3 vesicles undergo Ca2+ -independent cycling and modulate glutamate transporter trafficking.Group II metabotropic glutamate receptor interactions with NHERF scaffold proteins: Implications for receptor localization in brain.

P2860

Q24635165-CD8B97DF-17F9-4C17-9512-9CDF280175A1 Q28343696-CE59FC73-432C-4A64-9E8E-7C867509CFB7 Q30371933-C961650B-0D73-4045-AF6B-F5F046B6D50C Q30486707-5DD9C59A-AAD7-4B0A-BB92-41734861FF52 Q31426903-8B955BFC-4923-4DF7-9955-80D220092865 Q33187534-5CF2F12D-AA09-4726-9FE1-A159F4CDE70B Q33918068-0C5C0B71-8FC4-4AC6-ADD7-154509FDAAA3 Q33946539-D1BA123C-2259-4112-90CD-949F81C6FE35 Q34632695-2075F3FF-A683-408B-9B47-B986282D7016 Q35042763-C453C17F-7DC1-49E7-BBF5-6EFE05E514B1 Q36976781-E35248B5-8011-4312-A3AE-2E0F302A7AE0 Q37208500-481030DA-F103-4010-A795-591F9046D2A1 Q37220392-3D75BCDB-8FB9-447D-8E59-C9E7A4B36ED0 Q37280041-E69C798C-B03A-4F19-9562-6F7B3AF4BB19 Q37881198-23A160C7-1E90-425B-AD56-D3ED5AF488D8 Q38035216-84563B0A-BD23-4AB9-AFC7-81A1C6A0578C Q38139547-7BF2F409-2BC8-4D8B-A9B8-5242647C21DB Q38255981-45C81C76-721E-48A1-BF31-F94BB5E9C8DF Q38649976-B21B6A4E-C218-489B-9555-4F254B950867 Q39626308-8E6D86E4-F96C-44A0-A1D9-BE810D7A1410 Q40410370-8A73FA75-2365-4D8C-84D9-2A11853E17BD Q41871183-CDE4154E-DC94-4489-86C0-3DBDD3A26EB4 Q43112647-A39CE0F4-7C99-4827-ADBF-A2C4E85959FA Q43626799-817C1B10-EA92-4662-83BB-4298FEFC0243 Q43698175-CB15F412-2F6C-45B9-AA98-616F3BE9D47A Q44299700-AFA7E143-75E5-453A-9723-977516702530 Q44528186-C4608E38-D86A-48BC-B92D-A4C3BA4CD2C6 Q46423982-93894EBE-AAB4-495D-BE8B-959BB62375F1 Q46715544-7FD5F567-E53A-4F18-AC5C-F39D30F057BA Q47986411-915DC7AC-2467-4DF2-BAAF-FF92FB465685 Q48167050-13721BDB-80CB-4762-9ADE-5C3A2E3691C1 Q48234551-B55CEE9E-6627-4221-BE48-54356D7410A3 Q51065760-62B044B3-FEA1-4FFE-8338-AEAB3DEEC40F

P2860

LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors.

http://www.wikidata.org/entity/Q34425580

description

1997 nî lūn-bûn

@nan

1997 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

1997 թվականի հունվարին հրատարակված գիտական հոդված

@hy

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

name

LY354740 is a potent and highl ...... ing human glutamate receptors.

@ast

LY354740 is a potent and highl ...... ing human glutamate receptors.

@en

LY354740 is a potent and highl ...... ing human glutamate receptors.

@nl

type

label

LY354740 is a potent and highl ...... ing human glutamate receptors.

@ast

LY354740 is a potent and highl ...... ing human glutamate receptors.

@en

LY354740 is a potent and highl ...... ing human glutamate receptors.

@nl

prefLabel

LY354740 is a potent and highl ...... ing human glutamate receptors.

@ast

LY354740 is a potent and highl ...... ing human glutamate receptors.

@en

LY354740 is a potent and highl ...... ing human glutamate receptors.

@nl

P1433

Q34425580-DE4832D6-1834-41F2-8E69-A8E92E3BC1C2

P1476

Q34425580-32CD4C40-C422-46AF-86DA-8A6A7C8D8DFA

P2093

Q34425580-2413AB55-37A7-42DB-A2C5-F0A4125381AB

Q34425580-31AFBA62-0368-4D1A-82BA-53902939AE9A

Q34425580-3A0FD460-6815-4B1B-AE66-744DBCA55D66

Q34425580-52B7D016-0FAF-498B-BDB4-312FC9E9789C

Q34425580-6E5AC526-348A-4D74-A14E-609D58154B99

Q34425580-8AD22008-7A42-435B-866C-50178BED20E6

Q34425580-BAE4C21C-C3C6-46C5-9B9F-D386F64172C4

Q34425580-BCBBC7C8-32A8-43C2-A277-45BC3B0C0203

Q34425580-D3130171-5AFB-49E3-9456-0E79E93F97A6

Q34425580-D94B152E-3E1A-4EF6-907C-89DF1AB4F187

P304

Q34425580-807F3AA8-E193-4437-95D1-11E61905DB16

P31

Q34425580-8816536D-3EA7-4BBA-B833-4076D8C9EE00

P356

Q34425580-7BC51A1D-7B73-4A29-89E9-852FCD6DF694

P433

Q34425580-E1B3B02C-F26E-430B-AFF4-2B82F63CFB54

P478

Q34425580-C7FD8BCE-0F6E-4648-8942-B4201B9C428C

P577

Q34425580-E5FF7CD6-F1B6-4395-B00E-7826967E212C

P698

Q34425580-67F496D7-B746-4E11-8586-3E1E7105B296

P356

S0028-3908(96)00160-8

P1433

Neuropharmacology

P1476

LY354740 is a potent and highl ...... ing human glutamate receptors.

@en

P2093

B G Johnson

http://www.w3.org/2001/XMLSchema#string

C R Salhoff

http://www.w3.org/2001/XMLSchema#string

D Bleakman

http://www.w3.org/2001/XMLSchema#string

D D Schoepp

http://www.w3.org/2001/XMLSchema#string

J A Monn

http://www.w3.org/2001/XMLSchema#string

J P Burnett

http://www.w3.org/2001/XMLSchema#string

N G Mayne

http://www.w3.org/2001/XMLSchema#string

R A Wright

http://www.w3.org/2001/XMLSchema#string

R Belegaje

http://www.w3.org/2001/XMLSchema#string

S L Cockerman

http://www.w3.org/2001/XMLSchema#string

P304

1-11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0028-3908(96)00160-8

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

1997-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9144636

http://www.w3.org/2001/XMLSchema#string